EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives

Evangelos Koustas, Eleni-Myrto Trifylli, Vaios Oraiopoulos iD, Michalis V Karamouzis iD, Panagiotis Sarantis iD

Genes · 09.06.2026 · 17 (6) · 674

DOI: 10.3390/genes17060674 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 09.06.2026. Verfasst von Evangelos Koustas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Department, General Hospital Evangelismos, Ipsilantou 45-47, 106 76 Athens, Greece. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immunotherapy, Microsatellite Instability, Microsatellite Repeats. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic armamentarium for colorectal cancer (CRC) has been significantly expanded with the introduction of immunotherapy, particularly immune checkpoint inhibitors (ICIs). However, the response to immunotherapy is strongly dependent on microsatellite instability (MSI) status. Tumors with high MSI (MSI-H) and/or mismatch repair deficiency (dMMR) exhibit high tumor mutational burden (TMB), increased neoantigen load, and enhanced immunogenicity, leading to improved responses to ICIs compared with microsatellite-stable (MSS) and/or mismatch repair-proficient (pMMR) tumors. This has changed the treatment landscape of this small subgroup of metastatic CRC (mCRC), including the approval of pembrolizumab as a first-line option. In contrast, most mCRC cases are MSS/pMMR and are resistant or poorly responsive to ICIs, with no established standard immunotherapy strategy. Therefore, current approaches aim to convert these “cold” tumors into “hot,” immunologically active tumors. This review summarizes the distinct molecular basis of MSI phenotypes and their interaction with the tumor microenvironment, and provides relevant insights into current clinical evidence for prognostic and predictive biomarkers beyond MSI status, as well as novel therapeutic strategies to overcome resistance in MSS disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmunotherapyMicrosatellite InstabilityMicrosatellite RepeatsHumansPhenotypeImmune Checkpoint InhibitorsTumor MicroenvironmentDNA Mismatch RepairBiomarkers, Tumor

Stichwörter der Autor:innen

checkpoint inhibitorscolorectal cancerimmunotherapymicrosatellite instability

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Oncology Department, General Hospital Evangelismos, Ipsilantou 45-47, 106 76 Athens, Greece.
  • Institute of Molecular Medicine and Biomedical Research, 115 27 Athens, Greece.
  • University Clinic of Internal Medicine, General and Oncology Hospital "Agioi Anargyroi", National and Kapodistrian University of Athens, Timiou Stavrou 14, 145 64 Kifisia, Greece.

ORCID-Profile: Vaios Oraiopoulos, Michalis V Karamouzis, Panagiotis Sarantis

Zitieren

APA

Koustas, E., Trifylli, E. M., Oraiopoulos, V., Karamouzis, M. V., & Sarantis, P. (2026). Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives. Genes, 17(6), 674. https://doi.org/10.3390/genes17060674

Vancouver

Koustas E, Trifylli EM, Oraiopoulos V, Karamouzis MV, Sarantis P. Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives. Genes. 2026;17(6):674. doi:10.3390/genes17060674

BibTeX
@article{Koustas2026,
  author = {Koustas, Evangelos and Trifylli, Eleni-Myrto and Oraiopoulos, Vaios and Karamouzis, Michalis V and Sarantis, Panagiotis},
  title = {Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives},
  journal = {Genes},
  year = {2026},
  volume = {17},
  number = {6},
  pages = {674},
  doi = {10.3390/genes17060674}
}
Kostenlos starten →